2017
Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2017, 19: 155-163. PMID: 28134564, PMCID: PMC5359676, DOI: 10.1089/dia.2016.0421.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemGlucose valuesDiabetic ketoacidosis eventsMulticenter pivotal trialStudy phaseBlood sample testingType 1 diabetesClosed-loop insulin delivery systemBlood glucose valuesHome useContinuous glucose monitoringSensor glucose valuesHCl therapyKetoacidosis eventsHybrid closed-loop systemPivotal trialsInsulin delivery systemsGlucose outcomesMedtronic MiniMedType 1Glucose monitoringInsulin deliveryAdultsStayAdolescents
2015
CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes
Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R, Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia 2015, 58: 1167-1174. PMID: 25773405, PMCID: PMC4416994, DOI: 10.1007/s00125-015-3559-y.Peer-Reviewed Original ResearchConceptsC-peptide levelsType 1 diabetesHigher C-peptide levelsC-peptideGlucose levelsTime pointsGlucose valuesMixed meal tolerance testAims/hypothesisThe aimCGM glucose levelsC-peptide responseWeeks of diagnosisOnset of diabetesLower glucose variabilityConclusions/interpretationInMethodsA secondary analysisSensor glucose levelsCGM glucose valuesAdditional time pointsHypothesisThe aimGlucose variabilityTolerance testContinuous glucose monitoring dataInsulin secretionCGM metrics
2014
Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose
Sherr JL, Collazo M, Cengiz E, Michaud C, Carria L, Steffen AT, Weyman K, Zgorski M, Tichy E, Tamborlane WV, Weinzimer SA. Safety of Nighttime 2-Hour Suspension of Basal Insulin in Pump-Treated Type 1 Diabetes Even in the Absence of Low Glucose. Diabetes Care 2014, 37: 773-779. PMID: 24170766, PMCID: PMC3931387, DOI: 10.2337/dc13-1608.Peer-Reviewed Original ResearchConceptsBlood β-hydroxybutyrate levelsΒ-hydroxybutyrate levelsBasal insulinBlood glucose levelsBasal insulin infusionGlucose levelsBlood glucoseInsulin infusionMorning blood glucose levelsType 1 diabetic subjectsUsual basal ratesBasal rateLow glucose levelsSignificant ketonemiaDiabetic ketoacidosisDiabetic subjectsControl nightSensor-augmented pump systemGlucose valuesType 1Experimental nightInsulinLow glucoseNext morningInfusion
2013
Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes
Sherr JL, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA. Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise in Type 1 Diabetes. Diabetes Care 2013, 36: 2909-2914. PMID: 23757427, PMCID: PMC3781513, DOI: 10.2337/dc13-0010.Peer-Reviewed Original ResearchConceptsNocturnal hypoglycemiaType 1 diabetesAfternoon exerciseInsulin deliveryAntecedent exerciseTarget blood glucose rangeCL insulin deliveryClosed-loop insulin deliveryLoop insulin deliveryTarget rangeBlood glucose levelsBlood glucose rangeMaximum heart rateCL controlBrisk treadmillReduced hypoglycemiaSedentary dayExercise dayPercentage of timeGlucose levelsHeart rateGlucose valuesType 1Random orderStudy periodDeveloping parent expertise: A framework to guide parental care following diagnosis of Type 1 diabetes in a young child
Niedel S, Traynor M, Tamborlane W, Acerini C, McKee M. Developing parent expertise: A framework to guide parental care following diagnosis of Type 1 diabetes in a young child. Journal Of Health Services Research & Policy 2013, 18: 70-76. PMID: 23620579, DOI: 10.1177/1355819613475602.Peer-Reviewed Original ResearchType 1 diabetesHealth professionalsOutpatient pediatric diabetes clinicPediatric diabetes clinicExpert health care providersHealth care providersYears of ageBlood glucose valuesYoung childrenHealth professional training programsDiabetes clinicClinical guidelinesChronic diseasesCare providersNeeds of parentsDiabetesGlucose valuesChild's diseaseChild's diabetesDiseaseDiagnosisParents' expertiseChildrenParental expertiseClinicians
2010
Statement by the American Association of Clinical Endocrinologists Consensus Panel on Continuous Glucose Monitoring
Blevins TC, Bode BW, Garg SK, Grunberger G, Hirsch IB, Jovanovič L, Nardacci E, Orzeck EA, Roberts VL, Tamborlane WV, Rothermel C. Statement by the American Association of Clinical Endocrinologists Consensus Panel on Continuous Glucose Monitoring. Endocrine Practice 2010, 16: 730-745. PMID: 21356637, DOI: 10.4158/ep.16.5.730.Peer-Reviewed Original Research
2009
Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system.
Cengiz E, Swan KL, Tamborlane WV, Steil GM, Steffen AT, Weinzimer SA. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technology & Therapeutics 2009, 11: 207-10. PMID: 19344194, PMCID: PMC2842075, DOI: 10.1089/dia.2008.0102.Peer-Reviewed Original Research
2008
Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
White NH, Chase HP, Arslanian S, Tamborlane WV, . Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes. Diabetes Care 2008, 32: 387-393. PMID: 19106380, PMCID: PMC2646014, DOI: 10.2337/dc08-0800.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsInsulin glargineType 1 diabetesGlucose variabilityLente insulinPediatric patientsDaily injectionsBasal insulin componentOpen-label studySubset of patientsContinuous glucose monitoring systemMDI regimenGlucose monitoring systemGlycemic excursionsInsulin componentInsulin lisproContinuous glucose monitoring dataGlargineGlucose valuesGlucose monitoring dataType 1PatientsInsulinGreater reductionDiabetes